-
Mashup Score: 646An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations - 2 month(s) ago
ML2006a4 has improved affinity for SARS-CoV-2 Mpro and reduced sensitivity to mutations conferring resistance to nirmatrelvir or ensitrelvir.
Source: www.science.orgCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 3752The role of COVID-19 vaccines in preventing post-COVID-19 thromboembolic and cardiovascular complications - 2 month(s) ago
Objective To study the association between COVID-19 vaccination and the risk of post-COVID-19 cardiac and thromboembolic complications. Methods We conducted a staggered cohort study based on national vaccination campaigns using electronic health records from the UK, Spain and Estonia. Vaccine rollout was grouped into four stages with predefined enrolment periods. Each stage included all individuals eligible for vaccination, with no previous SARS-CoV-2 infection or COVID-19 vaccine at the start date. Vaccination status was used as a time-varying exposure. Outcomes included heart failure (HF), venous thromboembolism (VTE) and arterial thrombosis/thromboembolism (ATE) recorded in four time windows after SARS-CoV-2 infection: 0–30, 31–90, 91–180 and 181–365 days. Propensity score overlap weighting and empirical calibration were used to minimise observed and unobserved confounding, respectively. Fine-Gray models estimated subdistribution hazard ratios (sHR). Random effect meta-analyses were
Source: heart.bmj.comCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 3752The role of COVID-19 vaccines in preventing post-COVID-19 thromboembolic and cardiovascular complications - 2 month(s) ago
Objective To study the association between COVID-19 vaccination and the risk of post-COVID-19 cardiac and thromboembolic complications. Methods We conducted a staggered cohort study based on national vaccination campaigns using electronic health records from the UK, Spain and Estonia. Vaccine rollout was grouped into four stages with predefined enrolment periods. Each stage included all individuals eligible for vaccination, with no previous SARS-CoV-2 infection or COVID-19 vaccine at the start date. Vaccination status was used as a time-varying exposure. Outcomes included heart failure (HF), venous thromboembolism (VTE) and arterial thrombosis/thromboembolism (ATE) recorded in four time windows after SARS-CoV-2 infection: 0–30, 31–90, 91–180 and 181–365 days. Propensity score overlap weighting and empirical calibration were used to minimise observed and unobserved confounding, respectively. Fine-Gray models estimated subdistribution hazard ratios (sHR). Random effect meta-analyses were
Source: heart.bmj.comCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 7
npj Vaccines – Modulating the immune response to SARS-CoV-2 by different nanocarriers delivering an mRNA expressing trimeric RBD of the spike protein: COVARNA Consortium
Source: www.nature.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 2330stats - 3 month(s) ago
The 2023-2024 fall and winter virus season, four years since the start of the COVID-19 pandemic, provided ongoing evidence of the changing face of respiratory diseases. COVID-19 remains an important public health threat, but it is no longer the emergency that it once was, and its health impacts increasingly resemble those of other respiratory viral illnesses, including influenza and RSV. This reality enables CDC to provide updated guidance proportionate to the current level of risk COVID-19 poses while
Source: www.cdc.govCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 1
Nature Communications – SARS-CoV-2 can be spread by aerosols. Here the authors show that between 50-60% of ambulatory COVID-19 patients exhale culturable virus and that this is associated with…
Source: www.nature.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 3Outcomes in Hematopoietic Cell Transplant and Chimeric Antigen Receptor T Cell Therapy Recipients with Pre-Cellular Therapy SARS-CoV-2 Infection - 3 month(s) ago
Hematopoietic cell transplant and chimeric antigen receptor T cell therapy recipients with SARS-CoV-2 infection shortly prior to cellular therapy experienced fr
Source: academic.oup.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 22Dispersion patterns of SARS-CoV-2 variants Gamma, Lambda and Mu in Latin America and the Caribbean - 3 month(s) ago
Nature Communications – Genomic surveillance has been important for tracking the evolution and spread of SARS-CoV-2. Here, the authors analyse ~300,000 SARS-CoV-2 genomes from two years of…
Source: www.nature.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 691Effectiveness of XBB.1.5 vaccines and antiviral drugs against severe outcomes of omicron infection in the USA - 3 month(s) ago
In the fall of 2023, the US Food and Drug Administration (FDA) authorised the use of the updated Moderna (Sept 11), Pfizer-BioNTech (Sept 11), and Novavax (Oct 3) COVID-19 vaccines containing a monovalent component of the XBB.1.5 variant “to provide better protection against serious consequences of COVID-19, including hospitalization and death”, with neither the FDA nor the companies providing clinical evidence.1–2 The National Institutes of Health Guidelines prefer ritonavir-boosted nirmatrelvir to molnupiravir for outpatient treatment of symptomatic patients with COVID-19 at high risk of progressing to severe disease.
Source: www.thelancet.comCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 691Effectiveness of XBB.1.5 vaccines and antiviral drugs against severe outcomes of omicron infection in the USA - 3 month(s) ago
In the fall of 2023, the US Food and Drug Administration (FDA) authorised the use of the updated Moderna (Sept 11), Pfizer-BioNTech (Sept 11), and Novavax (Oct 3) COVID-19 vaccines containing a monovalent component of the XBB.1.5 variant “to provide better protection against serious consequences of COVID-19, including hospitalization and death”, with neither the FDA nor the companies providing clinical evidence.1–2 The National Institutes of Health Guidelines prefer ritonavir-boosted nirmatrelvir to molnupiravir for outpatient treatment of symptomatic patients with COVID-19 at high risk of progressing to severe disease.
Source: www.thelancet.comCategories: General Medicine News, Expert PicksTweet
"Drug design at the atomic level" vs Covid Report of a new oral drug vs #SARSCoV2 which is more potent and less sensitive to mutations than Paxolvid with pre-clinical data https://t.co/lpjS9193NY @ScienceTM @M_Westberg_